NextCure, Inc. has a disclosed 12.7% equity position held through a chain of affiliated entities ultimately controlled by Simcere Pharmaceutical Group Limited. The reporting group states that Simcere Zaiming, Inc. directly holds 338,636 shares of NextCure common stock and that Jiangsu Simcere Zaiming and Hainan Simcere Zaiming may be deemed to beneficially own those same shares through ownership chains. Two individual reporting persons, Jinsheng Ren and Renhong Tang, are disclosed as having shared voting and dispositive power over the 338,636 shares. The ownership percentage is calculated against 2,676,152 shares outstanding as reported by the issuer in its S-3 filing, and the Reporting Persons state the holdings were not acquired to influence control of the issuer.
Positive
Material ownership disclosed: Reporting Persons collectively disclose a significant 12.7% stake represented by 338,636 shares.
Clear ownership chain: The filing details the corporate chain from Simcere Zaiming, Inc. up to Simcere Pharmaceutical Group Limited, aiding transparency.
Voting/dispositive powers specified: The filing differentiates sole corporate powers and shared individual powers, clarifying control dynamics.
Negative
None.
Insights
TL;DR: A single corporate group discloses a >5% stake (12.7%) in NextCure via a structured ownership chain, reported for regulatory transparency.
The Schedule 13G shows Simcere Zaiming, Inc. as the direct holder of 338,636 shares, with beneficial ownership imputed to parent entities up the chain to Simcere Pharmaceutical Group Limited. The filing clarifies voting and dispositive powers: the corporate entities report sole voting and dispositive power, while two individuals report shared power. This is a routine large-shareholder disclosure that provides clarity on ownership concentration and governance links without indicating an intent to change control.
TL;DR: The disclosure maps control relationships and shared rights among corporate and individual reporting persons, improving investor visibility.
The document identifies the ownership chain and specifies how beneficial ownership is attributed under Section 13(d) rules. It names the individuals who may be deemed to share voting and investment power and attaches a joint filing agreement and power of attorney exhibits. For shareholders and boards, this filing clarifies which external parties hold meaningful influence through equity and corporate relationships.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
NEXTCURE, INC.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
65343E207
(CUSIP Number)
06/20/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
65343E207
1
Names of Reporting Persons
Simcere Zaiming, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
338,636.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
338,636.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
338,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
12.7 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc.
Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).
SCHEDULE 13G
CUSIP No.
65343E207
1
Names of Reporting Persons
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CHINA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
338,636.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
338,636.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
338,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
12.7 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. may deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc.
Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).
SCHEDULE 13G
CUSIP No.
65343E207
1
Names of Reporting Persons
Hainan Simcere Zaiming Pharmaceutical Co., Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CHINA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
338,636.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
338,636.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
338,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
12.7 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Hainan Simcere Zaiming Pharmaceutical Co., Ltd. may deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc.
Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).
SCHEDULE 13G
CUSIP No.
65343E207
1
Names of Reporting Persons
Simcere Pharmaceutical Group Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CHINA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
338,636.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
338,636.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
338,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
12.7 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Simcere Pharmaceutical Group Limited is the controlling shareholder of Hainan Simcere Zaiming Pharmaceutical Co., Ltd. through investment in several intermediate companies. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Simcere Pharmaceutical Group Limited may be deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc.
Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).
SCHEDULE 13G
CUSIP No.
65343E207
1
Names of Reporting Persons
Ren Jinsheng
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CHINA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
338,636.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
338,636.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
338,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
12.7 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Note to Rows (6), (8) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Pharmaceutical Group Limited and a director of Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Jinsheng Ren may thereby be deemed to beneficially own the 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., sharing the voting power and investment power over such shares with Mr. Renhong Tang.
Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).
SCHEDULE 13G
CUSIP No.
65343E207
1
Names of Reporting Persons
Tang Renhong
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CHINA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
338,636.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
338,636.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
338,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
12.7 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Note to Rows (6), (8) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which is 100% owned by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Renhong Tang is a director of Simcere Pharmaceutical Group Limited, the chief executive officer and chairman of the board of directors of Hainan Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. and the chief executive officer and sole director of Simcere Zaiming, Inc. Accordingly, Mr. Renhong Tang may thereby be deemed to beneficially own the 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., sharing the voting power and investment power over such shares with Mr. Jinsheng Ren.
Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
NEXTCURE, INC.
(b)
Address of issuer's principal executive offices:
9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705
Item 2.
(a)
Name of person filing:
(i) Simcere Zaiming, Inc., a Delaware corporation ("Simcere Zaiming"), with its principal business address at 20 Acorn Park Dr., Cambridge, MA 02140;
(ii) Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., a limited liability company incorporated in P. R. China ("Jiangsu Zaiming"), is the sole shareholder of Simcere Zaiming, and its principal business address is at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China;
(iii) Hainan Simcere Zaiming Pharmaceutical Co., Ltd., a limited liability company incorporated in P. R. China ("Hainan Zaiming"), is the sole shareholder of Jiangsu Zaiming, and its principal business address is at No 20, Yaoguyiheng Road, Xiuying District, Haikou, Hainan, P. R. China.
(iv) Simcere Pharmaceutical Group Limited, a company incorporated in Hong Kong ("Simcere Group") and the controlling shareholder of Hainan Zaiming through several intermediate companies, and its principal business address is at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China.
(v) Mr. Jinsheng Ren, citizen of People's Republic of China, the chief executive officer and chairman of the board of directors of Simcere Group and a director of Hainan Zaiming, with his business address at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China; and
(vi) Mr. Renhong Tang, citizen of People's Republic of China, a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming, with his business address at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China.
The persons and entities listed in items (i) to (vi) are collectively referred to herein as "Reporting Persons."
The Reporting Persons have entered into a joint filing agreement, a copy of which is attached hereto as Exhibit 99.1.
(b)
Address or principal business office or, if none, residence:
See Item 2(a) above.
(c)
Citizenship:
See Item 2(a) above.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
65343E207
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See Row 9 of the cover page for each Reporting Person.
Each of Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this Schedule 13G shall not be deemed to be an admission that the Reporting Persons hereunder are the beneficial owners of any of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
(b)
Percent of class:
See Row 11 of the cover page for each Reporting Person.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Row 5 of the cover page for each Reporting Person.
(ii) Shared power to vote or to direct the vote:
See Row 6 of the cover page for each Reporting Person.
(iii) Sole power to dispose or to direct the disposition of:
See Row 7 of the cover page for each Reporting Person.
(iv) Shared power to dispose or to direct the disposition of:
See Row 8 of the cover page for each Reporting Person.
Item 5.
Ownership of 5 Percent or Less of a Class.
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Simcere Zaiming, Inc.
Signature:
/s/ Renhong Tang
Name/Title:
Renhong Tang/Chief Executive Officer
Date:
08/19/2025
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.
Signature:
/s/ Renhong Tang
Name/Title:
Renhong Tang/Director and Attorney-in-Fact
Date:
08/19/2025
Hainan Simcere Zaiming Pharmaceutical Co., Ltd.
Signature:
/s/ Renhong Tang
Name/Title:
Renhong Tang/Chief Executive Officer and Chairman of the Board of Directors
Date:
08/19/2025
Simcere Pharmaceutical Group Limited
Signature:
/s/ Jinsheng Ren
Name/Title:
Jinsheng Ren / Chief Executive Officer and Chairman of the Board of Directors
Date:
08/19/2025
Ren Jinsheng
Signature:
/s/ Jinsheng Ren
Name/Title:
Jinsheng Ren
Date:
08/19/2025
Tang Renhong
Signature:
/s/ Renhong Tang
Name/Title:
Renhong Tang
Date:
08/19/2025
Exhibit Information
24 Power of Attorney.
99.1 Joint Filing Agreement, dated as of August 19, 2025, by and among the Reporting Persons.
What stake in NextCure (NXTC) do the Reporting Persons disclose?
They disclose beneficial ownership of 338,636 shares, representing 12.7% of NextCure's outstanding common stock.
Which entity directly holds the NextCure shares reported in this Schedule 13G?
The direct holder is Simcere Zaiming, Inc., which is stated to own the 338,636 shares.
Why are other Simcere entities and individuals listed as Reporting Persons?
Parent companies (Jiangsu and Hainan Simcere Zaiming and Simcere Pharmaceutical Group Limited) and two individuals are listed because they may be deemed to beneficially own or share voting/dispositive power over the shares.
What outstanding share base is used to calculate the 12.7% stake?
The percentage is based on 2,676,152 shares outstanding as reported by the issuer in its Form S-3.
Does the filing state an intent to influence control of NextCure?
The Reporting Persons certify that the securities were not acquired for the purpose of changing or influencing control of the issuer.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
You have made too many password recovery requests. Please try again tomorrow.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
